ADMA Q4 2017 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+260.7% YoY

Gross Profit

$79,9780.7% margin

Operating Income

-$11M-87.8% margin

Net Income

-$13M-108.2% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+153.8%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$15M

Stock-Based Comp.

$508,689

Balance Sheet

Total Assets

$108M

Total Liabilities

$68M

Stockholders' Equity

$40M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$3M	+260.7%
Gross Profit	$79,978	$1M	-93.9%
Operating Income	-$11M	-$4M	-167.3%
Net Income	-$13M	-$5M	-184.8%